Entropy-driven binding of gut bacterial beta-glucuronidase inhibitors ameliorates irinotecan-induced toxicity.
Lin, H.Y., Chen, C.Y., Lin, T.C., Yeh, L.F., Hsieh, W.C., Gao, S., Burnouf, P.A., Chen, B.M., Hsieh, T.J., Dashnyam, P., Kuo, Y.H., Tu, Z., Roffler, S.R., Lin, C.H.(2021) Commun Biol 4: 280-280
- PubMed: 33664385 
- DOI: https://doi.org/10.1038/s42003-021-01815-w
- Primary Citation of Related Structures:  
6LD0, 6LD6, 6LDB, 6LDC, 6LDD, 6LEG, 6LEJ, 6LEL, 6LEM - PubMed Abstract: 
Irinotecan inhibits cell proliferation and thus is used for the primary treatment of colorectal cancer. Metabolism of irinotecan involves incorporation of β-glucuronic acid to facilitate excretion. During transit of the glucuronidated product through the gastrointestinal tract, an induced upregulation of gut microbial β-glucuronidase (GUS) activity may cause severe diarrhea and thus force many patients to stop treatment ...